UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease

International journal of molecular sciences, 2023-06, Vol.24 (13), p.10523

2023

Volltextzugriff (PDF)

The challenges of clinical trials in fragile X syndrome

Psychopharmacology, 2014-03, Vol.231 (6), p.1237-1250

2014

Volltextzugriff (PDF)

Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model

Journal of neuroinflammation, 2023-02, Vol.20 (1), p.29-29, Article 29

2023

Volltextzugriff (PDF)

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity

PLoS pathogens, 2017-11, Vol.13 (11), p.e1006733

2017

Volltextzugriff (PDF)

In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

Journal of cerebral blood flow and metabolism, 2017-08, Vol.37 (8), p.2716-2727

2017

Volltextzugriff (PDF)

Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes

Journal of neuroinflammation, 2016-08, Vol.13 (1), p.189-189, Article 189

2016

Volltextzugriff (PDF)

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

Neurobiology of disease, 2011-06, Vol.42 (3), p.311-317

2011

Volltextzugriff (PDF)

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Biological psychiatry : cognitive neuroscience and neuroimaging, 2017-07, Vol.2 (5), p.449-456

2017

Volltextzugriff (PDF)

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Expert opinion on investigational drugs, 2014-01, Vol.23 (1), p.125-134

2014

Volltextzugriff (PDF)

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

Parkinson's disease, 2013-01, Vol.2013 (2013), p.1-11

2013

Volltextzugriff (PDF)

Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

British journal of pharmacology, 2001-04, Vol.132 (7), p.1423-1430

2001

Volltextzugriff (PDF)

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1267

2000

Volltextzugriff (PDF)

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Molecular pharmacology, 1999-03, Vol.55 (3), p.453

1999

Volltextzugriff (PDF)

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

Clinical epigenetics, 2016-02, Vol.8 (15), p.15-15, Article 15

2016

Volltextzugriff (PDF)

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

BMC medical genetics, 2012-03, Vol.13 (1), p.13-13, Article 13

2012

Volltextzugriff (PDF)

Increased Seizure Susceptibility in Mice Lacking Metabotropic Glutamate Receptor 7

The Journal of neuroscience, 2001-11, Vol.21 (22), p.8734-8745

2001

Volltextzugriff (PDF)

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

ChemMedChem, 2010-10, Vol.5 (10), p.1693-1696

2010

Volltextzugriff (PDF)

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

The Journal of pharmacology and experimental therapeutics, 1999-07, Vol.290 (1), p.170

1999

Volltextzugriff (PDF)

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Nature reviews. Drug discovery, 2018-04, Vol.17 (4), p.280-299

2018

Volltextzugriff (PDF)

Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers

European journal of nuclear medicine and molecular imaging, 2008-04, Vol.35 (4), p.766-770

2008

Volltextzugriff (PDF)

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development

Psychopharmacology, 2014-03, Vol.231 (6), p.1217-1226

2014

Volltextzugriff (PDF)

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

Parkinsonism & related disorders, 2014-09, Vol.20 (9), p.947-956

2014

Volltextzugriff (PDF)

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

Science translational medicine, 2011-01, Vol.3 (64), p.64ra1

2011

Volltextzugriff (PDF)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

Human molecular genetics, 2018-06, Vol.27 (12), p.2039-2051

2018

Volltextzugriff (PDF)

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

Movement disorders, 2011-06, Vol.26 (7), p.1243-1250

2011

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(115)
Buchkapitel
(1)

Sprache

Englisch
(116)

Erscheinungsjahr

n.n

Thema

Science & Technology
(116)
Humans
(77)
Male
(56)
Female
(44)
Neurosciences & Neurology
(42)
Animals
(37)
Neurosciences
(33)
Middle Aged
(31)
Aged
(25)
Receptors, Metabotropic Glutamate - Antagonists & Inhibitors
(25)
Pharmacology & Pharmacy
(23)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Adult
(19)
Clinical Neurology
(18)
Neurology
(18)
Receptor, Metabotropic Glutamate 5
(17)
Cardiac & Cardiovascular Systems
(15)
Cardiovascular System & Cardiology
(15)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease

The challenges of clinical trials in fragile X syndrome

Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity

In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Increased Seizure Susceptibility in Mice Lacking Metabotropic Glutamate Receptor 7

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

Aktive Filter

Suchergebnisse filtern